Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2024)
Top diagnostic & research stocks in 2024 ranked by overall Zen Score. See the best diagnostic & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

Industry: Diagnostics & Research

Overview Zen Score Price Valuation Financials Forecast Earnings & Revenue Dividends Ownership

Ticker	Company	Country	Market Cap	Shares	Institutional %	Insider %	Net Insider (L12M)	Net Insider (L3M)
FONR	FONAR CORP	United States	$112.91M	6,710,807	47.70%	3.51%
IDXX	IDEXX LABORATORIES INC	United States	$39.70B	83,089,381	87.71%	1.68%	Net Selling	Net Selling
ICLR	ICON PLC	Ireland	$24.07B	82,495,086	95.64%	0.00%
STRR	STAR EQUITY HOLDINGS INC	United States	$13.49M	15,848,202	3.66%	96.34%	Net Buying	Net Selling
RVTY	REVVITY INC	United States	$12.28B	123,529,821	86.51%	2.53%	Net Buying	Net Buying
A	AGILENT TECHNOLOGIES INC	United States	$38.81B	293,055,284	87.43%	1.18%	Net Buying	Net Selling
MEDP	MEDPACE HOLDINGS INC	United States	$11.51B	30,759,281	27.34%	72.66%	Net Selling	Net Selling
NEOG	NEOGEN CORP	United States	$2.58B	216,607,746	98.57%	1.43%	Net Buying	Net Buying
TMO	THERMO FISHER SCIENTIFIC INC	United States	$206.49B	381,312,268	89.26%	0.87%	Net Selling	Net Selling
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	United States	$11.68B	51,349,770	96.79%	3.21%	Net Selling	Net Selling
QGEN	QIAGEN NV	Netherlands	$9.01B	228,202,755	61.40%	0.00%
SHC	SOTERA HEALTH CO	United States	$3.08B	282,832,200	61.96%	38.04%	Net Selling	Net Selling
ENZ	ENZO BIOCHEM INC	United States	$57.89M	51,225,734	31.93%	48.12%	Net Selling
LH	LABORATORY CORP OF AMERICA HOLDINGS	United States	$16.77B	84,100,000	95.77%	1.52%	Net Selling	Net Selling
DHR	DANAHER CORP	United States	$174.84B	739,701,725	75.94%	24.06%	Net Selling	Net Selling
CSTL	CASTLE BIOSCIENCES INC	United States	$527.04M	27,449,983	84.19%	15.81%	Net Selling	Net Selling
TWST	TWIST BIOSCIENCE CORP	United States	$1.64B	57,818,022	88.25%	11.75%	Net Selling	Net Selling
DGX	QUEST DIAGNOSTICS INC	United States	$13.94B	110,707,293	88.06%	1.77%	Net Selling	Net Selling
MTD	METTLER TOLEDO INTERNATIONAL INC	United States	$25.61B	21,478,705	94.58%	4.52%	Net Selling	Net Buying
XGN	EXAGEN INC	United States	$24.63M	17,235,751	36.96%	63.04%	Net Selling	Net Selling
WAT	WATERS CORP	United States	$17.42B	59,202,626	92.46%	7.54%	Net Selling	Net Selling
ACRS	ACLARIS THERAPEUTICS INC	United States	$87.24M	70,925,042	56.85%	43.15%	Net Selling	Net Selling
SERA	SERA PROGNOSTICS INC	United States	$317.45M	32,425,661	34.04%	21.12%	Net Selling	Net Selling
IQV	IQVIA HOLDINGS INC	United States	$41.23B	181,500,000	53.95%	46.05%	Net Selling	Net Selling
PRPO	PRECIPIO INC	United States	$9.59M	1,430,292	0.61%	99.39%	Net Buying	Net Buying
PSNL	PERSONALIS INC	United States	$61.11M	50,503,889	43.52%	18.39%	Net Selling	Net Buying
EXAS	EXACT SCIENCES CORP	United States	$11.52B	181,530,967	88.62%	3.40%	Net Selling	Net Selling
NTRA	NATERA INC	United States	$10.54B	120,757,877	78.43%	21.57%	Net Selling	Net Selling
OLK	OLINK HOLDING AB (PUBL)	Sweden	$2.77B	124,342,715	30.18%	0.00%
DRIO	DARIOHEALTH CORP	Israel	$33.86M	29,442,532	29.42%	53.98%
FLGT	FULGENT GENETICS INC	United States	$598.97M	29,784,771	48.02%	42.49%	Net Selling	Net Selling
GH	GUARDANT HEALTH INC	United States	$2.03B	121,712,724	64.42%	35.58%	Net Selling	Net Selling
STIM	NEURONETICS INC	United States	$113.97M	29,756,053	50.13%	49.87%	Net Selling	Net Selling
DMTK	DERMTECH INC	United States	$20.46M	34,623,443	15.75%	77.74%	Net Selling	Net Selling
NEO	NEOGENOMICS INC	United States	$1.76B	127,610,039	72.39%	27.61%	Net Selling	Net Selling
BNR	BURNING ROCK BIOTECH LTD	China	$81.92M	102,396,208	19.66%	0.00%
OCX	ONCOCYTE CORP	United States	$21.18M	8,273,073	5.82%	94.18%	Net Buying	Net Buying
RDNT	RADNET INC	United States	$3.26B	68,475,443	64.36%	35.64%	Net Selling
BGLC	BIONEXUS GENE LAB CORP	Malaysia	$15.00M	17,667,663	0.59%	97.91%
PRE	PRENETICS GLOBAL LTD	Hong Kong	$38.65M	12,114,922	10.11%	0.00%
APDN	APPLIED DNA SCIENCES INC	United States	$5.74M	16,978,703	9.45%	72.88%
LAB	STANDARD BIOTOOLS INC	United States	$736.90M	290,117,930	16.74%	33.34%	Net Buying	Net Buying
XWEL	XWELL INC	United States	$5.86M	4,183,435	1.65%	98.35%	Net Buying
MDXH	MDXHEALTH SA	Belgium	$6.20M	27,038,094	11.79%	88.21%
CDNA	CAREDX INC	United States	$417.85M	51,778,523	79.47%	20.53%	Net Selling	Net Selling
BDSX	BIODESIX INC	United States	$121.18M	96,942,061	17.45%	72.27%	Net Buying	Net Selling
ME	23ANDME HOLDING CO	United States	$243.87M	482,916,636	27.87%	2.59%	Net Buying	Net Selling
NDRA	ENDRA LIFE SCIENCES INC	United States	$2.57M	11,035,659	1.19%	8.73%	Net Buying
CHEK	CHECK-CAP LTD	Israel	$13.22M	5,849,756	1.07%	0.00%
ULS	UL SOLUTIONS INC	United States	N/A	200,000,000	0.00%	0.30%	Net Selling	Net Selling
PRPH	PROPHASE LABS INC	United States	$98.17M	18,045,209	9.36%	57.17%
NOTV	INOTIV INC	United States	$121.22M	25,790,680	18.17%	43.71%	Net Buying
AWH	ASPIRA WOMEN's HEALTH INC	United States	$43.57M	12,344,104	0.84%	99.16%	Net Buying
OPK	OPKO HEALTH INC	United States	$857.30M	696,991,667	17.43%	82.57%	Net Buying	Net Buying
VNRX	VOLITIONRX LTD	United States	$50.64M	82,068,442	7.76%	40.12%	Net Buying
GENE	GENETIC TECHNOLOGIES LTD	Australia	$563.24k	115,417,246	0.02%	0.00%
MYGN	MYRIAD GENETICS INC	United States	$1.66B	89,874,886	92.31%	7.69%	Net Selling	Net Selling
ISPC	ISPECIMEN INC	United States	$3.83M	9,087,467	4.31%	71.05%	Net Buying
BIAF	BIOAFFINITY TECHNOLOGIES INC	United States	$32.13M	11,514,354	1.36%	36.42%	Net Buying	Net Buying
ILMN	ILLUMINA INC	United States	$18.54B	158,900,000	89.29%	1.97%	Net Selling	Net Buying
PMD	PSYCHEMEDICS CORP	United States	$14.70M	5,742,761	22.46%	50.15%	Net Selling
MYNZ	MAINZ BIOMED NV	Germany	$19.13M	21,165,482	1.10%	0.00%
TRIB	TRINITY BIOTECH PLC	Ireland	$14.41M	153,310,280	3.93%	0.00%
MMA	ALTA GLOBAL GROUP LTD	Australia	N/A	10,223,079	0.00%	0.00%
CNTG	CENTOGENE NV	Germany	$12.72M	27,595,835	9.75%	0.00%
TTOO	T2 BIOSYSTEMS INC	United States	$16.48M	5,512,332	0.51%	99.49%	Net Selling

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Apr 2024?

According to Zen Score, the 3 best diagnostic & research stocks to buy right now are:

1. Fonar (NASDAQ:FONR)

Fonar (NASDAQ:FONR) is the top diagnostic & research stock with a Zen Score of 47, which is 19 points higher than the diagnostic & research industry average of 28. It passed 14 out of 33 due diligence checks and has strong fundamentals. Fonar has seen its stock return 7.65% over the past year, overperforming other diagnostic & research stocks by 17 percentage points.

2. Icon (NASDAQ:ICLR)

Icon (NASDAQ:ICLR) is the second best diagnostic & research stock with a Zen Score of 46, which is 18 points higher than the diagnostic & research industry average of 28. It passed 15 out of 33 due diligence checks and has strong fundamentals. Icon has seen its stock return 37.06% over the past year, overperforming other diagnostic & research stocks by 47 percentage points.

Icon has an average 1 year price target of $346.43, an upside of 18.71% from Icon's current stock price of $291.82.

Icon stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Icon, 71.43% have issued a Strong Buy rating, 28.57% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Idexx Laboratories (NASDAQ:IDXX)

Idexx Laboratories (NASDAQ:IDXX) is the third best diagnostic & research stock with a Zen Score of 46, which is 18 points higher than the diagnostic & research industry average of 28. It passed 15 out of 33 due diligence checks and has strong fundamentals. Idexx Laboratories has seen its stock lose -0.9% over the past year, overperforming other diagnostic & research stocks by 9 percentage points.

Idexx Laboratories has an average 1 year price target of $584.00, an upside of 22.23% from Idexx Laboratories's current stock price of $477.79.

Idexx Laboratories stock has a consensus Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Idexx Laboratories, 60% have issued a Strong Buy rating, 0% have issued a Buy, 40% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 7 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) has an annual dividend yield of 3.24%, which is 2 percentage points higher than the diagnostic & research industry average of 1.43%.

Qiagen Nv's dividend payout ratio of 85.3% indicates that its dividend yield is sustainable for the long-term.

2. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 2.29%, which is 1 percentage points higher than the diagnostic & research industry average of 1.43%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 37.4% indicates that its dividend yield is sustainable for the long-term.

3. Laboratory Of America Holdings (NYSE:LH)

Laboratory Of America Holdings (NYSE:LH) has an annual dividend yield of 1.44%, which is the same as the diagnostic & research industry average of 1.43%. Laboratory Of America Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Laboratory Of America Holdings's dividend has not shown consistent growth over the last 10 years.

Laboratory Of America Holdings's dividend payout ratio of 60% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -0.91% in the last day, and down -7.32% over the last week. Genetic Technologies was the among the top losers in the diagnostics & research industry, dropping -22.78% yesterday.

Genetic Technologies shares trading lower after the company announced a $2 million registered direct offering.

What are the most undervalued diagnostic & research stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostic & research stocks right now are:

1. Star Equity Holdings (NASDAQ:STRR)

Star Equity Holdings (NASDAQ:STRR) is the most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Star Equity Holdings has a valuation score of 71, which is 49 points higher than the diagnostic & research industry average of 22. It passed 5 out of 7 valuation due diligence checks.

Star Equity Holdings's stock has gained 6.38% in the past year. It has overperformed other stocks in the diagnostic & research industry by 16 percentage points.

2. Enzo Biochem (NYSE:ENZ)

Enzo Biochem (NYSE:ENZ) is the second most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Enzo Biochem has a valuation score of 71, which is 49 points higher than the diagnostic & research industry average of 22. It passed 5 out of 7 valuation due diligence checks.

Enzo Biochem's stock has dropped -53.69% in the past year. It has underperformed other stocks in the diagnostic & research industry by -44 percentage points.

3. Fonar (NASDAQ:FONR)

Fonar (NASDAQ:FONR) is the third most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Fonar has a valuation score of 71, which is 49 points higher than the diagnostic & research industry average of 22. It passed 5 out of 7 valuation due diligence checks.

Fonar's stock has gained 7.65% in the past year. It has overperformed other stocks in the diagnostic & research industry by 17 percentage points.

Are diagnostic & research stocks a good buy now?

46.81% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 13.68% over the next year.

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 36.3x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.